Information Provided By:
Fly News Breaks for July 17, 2017
VRX
Jul 17, 2017 | 10:18 EDT
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
News For VRX From the Last 2 Days
There are no results for your query VRX